Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

12.20USD
3:59pm EST
Change (% chg)

$0.52 (+4.45%)
Prev Close
$11.68
Open
$11.85
Day's High
$12.20
Day's Low
$11.71
Volume
6,449
Avg. Vol
14,577
52-wk High
$16.59
52-wk Low
$8.80

Select another date:

Thu, Jan 25 2018

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

BRIEF-Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios

* SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA

BRIEF-Summit highlights DMD biomarker phase 2 clinical trial data in presentations at 22nd WMS Congress

* Summit highlights DMD biomarker validation data and phase 2 clinical trial baseline characteristics in presentations at 22nd WMS Congress

BRIEF-Summit Therapeutics announces pricing of public offering $12.00 per ADS

* Summit Therapeutics announces pricing of public offering of 1,459,000 American Depositary Shares

BRIEF-Summit Therapeutics announces proposed public offering of $15 mln of American Depositary shares

* Summit Therapeutics announces proposed public offering of $15.0 million of American Depositary shares Source text for Eikon: Further company coverage:

BRIEF-Summit awarded BARDA contract worth up to $62 million

* Summit awarded BARDA contract worth up to $62 million to support the development of ridinilazole for the treatment of C. difficile infection

BRIEF-Summit announces positive top-line data from an exploratory phase 2 supporting Ridinilazole

* Summit announces positive top-line data from an exploratory phase 2 clinical trial supporting Ridinilazole as a highly selective antibiotic for the treatment of CDI

BRIEF-Summit Therapeutics reports financial results for Q2 ended July 31 2017

* Summit Therapeutics reports financial results for the second quarter and half year ended July 31 2017 and operational progress

Select another date: